



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/670,537	09/27/2000	Andrew P. Mazar	38369-169219	6771

7590 06/18/2003

CATHRYN CAMPBELL
CAMPBELL & FLORES LLP
4370 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122

[REDACTED] EXAMINER

JONES, DAMERON L

[REDACTED] ART UNIT

[REDACTED] PAPER NUMBER

1616

DATE MAILED: 06/18/2003

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/670,537	MAZAR ET AL.
	Examiner	Art Unit
	D. L. Jones	1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-49 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-49 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ . | 6) <input type="checkbox"/> Other: |

RESTRICTION INTO GROUPS

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-12, 24, 26, 28, 30, 32-34, 37, 40, 42, 44, 46, and 48, drawn to methods and a composition comprising an uPAR targeting protein or peptide that includes residues 13-30 of the uPAR bind site, comprise at least 38 amino acids, contain a diagnostic or therapeutic label, compete with labeled DFP-uPA, and is not a fusion protein as set forth in independent claim 1, classified in class 424, subclass 9.3.
 - II. Claims 13-20, 25, 27, 29, and 31, drawn to methods and a composition comprising an uPA compound that modifies the active sited of tcuPA and retains the uPA enzymatic endosite and binding, and has a chelator as set forth in independent claim 13, classified in class 530, subclass 300+.
 - III. Claims 21-23, 35, 36, 38, 39, 41, 43, 45, 47, and 49, drawn to methods and a composition comprising an uPA peptide compound that binds to the endosite and one or more exosites of tcuPA and modifies the endosite as set forth in independent claim 21, classified in class 424, subclass 9.1.
2. The inventions are distinct, each from the other because of the following reasons:
Inventions I-III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that

product (MPEP § 806.05(h)). In the instant case, the various products (see independent claims 1, 13, and 21) may be used in various methods such as (1) for inhibiting the invasiveness of tumor cells; (2) for treating a subject having a disease or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis; or (3) for inducing apoptosis.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

ELECTION OF SPECIES

4. Claims 1-49 are generic to a plurality of disclosed patentably distinct species comprising a protein or peptide as set forth in independent claim 1. In particular, the protein may be select from various ones such as uPA, scuPA, tcuPA, an N-terminal fragment of uPA, residues 1-135; an N-terminal fragment of uPA, residues 1-143; an N-terminal fragment of uPA, residues 1-43; or an N-terminal fragment of uPA, residues 4-43; or proteins or peptides as set forth in independent claims 13 and 21. Likewise, the peptides or proteins may contain various detectable labels (e.g., see claim 9), optionally, a chelator (e.g., see claim 16), be used for in vivo or in vitro purposes, and be used in various methods such as for treating cell migration, invasion, proliferation, and angiogenesis, to name a few.

Applicant is respectfully requested to elect a single disclosed species from the elected group above for search purposes, even though this requirement is traversed.

The elected species should identify all components associated with that group such as the detectable label, chelator, protein or peptide, method wherein the elected species is utilized, and amino acids (e.g., see claim 22).

5. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
6. Due to the complexity of the restriction requirement, a telephone call was not made to request an oral election to the above restriction requirement.
7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (703) 308-4640. The examiner can normally be reached on Mon.-Fri. (alternate Mon.), 6:45 a.m. - 4:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose' Dees can be reached on (703) 308- 4628. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.



D. L. Jones
Primary Examiner
Art Unit 1616

June 16, 2003